Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 7/20 | 0.82 |
| ▸ | ITGAM | P11215 | 7/20 | 0.82 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46561 | 0.90 | ITGB2 (1.00) | ITGB2ITGAMSLC1A3MEN1KMT2A | |
| SCHEMBL46548 | 0.84 | ITGB2 (0.73) | ITGB2ITGAMSLC1A3MEN1KMT2A | |
| SCHEMBL12340057 | 0.81 | ITGB2 (0.84) | ITGB2ITGAMSLC1A3MEN1KMT2A | |
| SCHEMBL684060 | 0.81 | ITGB2 (0.80) | ITGB2ITGAMSLC1A3MEN1KMT2A | |
| SCHEMBL46224 | 0.80 | ITGB2 (1.00) | ITGB2ITGAMSLC1A3MEN1KMT2A | |
| SCHEMBL5142920 | 0.79 | ITGB2 (0.79) | ITGB2ITGAMSLC1A3MEN1KMT2A | |
| SCHEMBL5142921 | 0.79 | ITGB2 (0.79) | ITGB2ITGAMSLC1A3MEN1KMT2A | |
| SCHEMBL16639742 | 0.78 | ITGB2 (0.53) | ITGB2ITGAMSLC1A3MEN1KMT2A | |
| SCHEMBL683064 | 0.76 | SLC1A3 (1.00) | ITGB2ITGAMSLC1A3MEN1KMT2A | |
| SCHEMBL46575 | 0.75 | ITGB2 (0.69) | ITGB2ITGAMSLC1A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ITGB8, ITGB3, ITGAM | ITGB2 5/4885ITGAM 3/4885SLC1A3 3928/4885 |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | ITGB2 2/4885ITGAM 9/4885SLC1A3 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.